Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Followed by BGD and Autologous Transplant in Refractory Hodgkin's Lymphoma
2024-515064-31-00Phase 2Authorised
- Sponsor
- Medical University of Gdańsk
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in Hodgkin lymphoma (HL), sponsored by Medical University of Gdańsk. Primary endpoints: Complete metabolic remission rate after Nivolumab + 2 cycles of BGD and Progression-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2024-515064-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515064-31-00.